Virax Biolabs Group Limited filed a Sticker Prospectus Supplement to increase the maximum aggregate offering amount of Ordinary Shares available for sale under its existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC. The new limit is set at $2,070,060.20, which excludes $3,658,152 of shares previously sold under the program. This amendment supplements the original agreement dated January 22, 2024, and related prospectus supplements from December 2023 and September 2024. The filing includes a legal opinion regarding the legality of the issuance. Virax Biolabs Group Limited operates in the biotechnology industry, specializing in viral vector manufacturing for gene therapy and vaccine development.

Virax Biolabs Group Limited convened an Extraordinary General Meeting on August 14, 2026, which lacked a quorum and was adjourned to August 21. At the reconvened meeting, shareholders approved by ordinary resolution an increase in authorized share capital from US$50,000 (2 million shares) to US$12,500,000 (500 million shares), creating 498 million new ordinary shares with a par value of US$0.025 each. However, shareholders rejected the special resolution required to adopt the fifth amended and restated memorandum and articles of association intended to reflect this revised capital structure. Virax Biolabs Group Limited operates in the biotechnology industry, specializing in viral vector manufacturing for gene therapy and vaccine development.

Virax Biolabs Group Limited is holding an Extraordinary General Meeting on August 14, 2026, to seek shareholder approval for increasing its authorized share capital from US$50,000 (2 million shares) to US$12.5 million (500 million shares). This creation of 498 million new ordinary shares is intended to provide funding and transactional flexibility for operations and business development related to ViraxImmune™. The company will also adopt a Fifth Amended and Restated Memorandum and Articles of Association to reflect this capital increase. Virax Biolabs Group Limited operates in the biotechnology industry, focusing on viral vector manufacturing and vaccine development.

Virax Biolabs Group Limited reported audited financial results for fiscal year 2026, showing $6.4 million in cash and $8.3 million in total assets as of March 31, 2026. The company completed the exercise of preferred investment options on July 10, 2026, generating approximately $3.3 million in gross proceeds. Following a 1-for-25 share consolidation, Nasdaq confirmed on July 13, 2026, that the company regained compliance with minimum bid price requirements. Additionally, the company entered a multi-country commercial supply agreement with Fosun Diagnostics for ImmuneSelect across six Southeast Asian markets. Biotechnology company focused on immune response detection and in vitro diagnostic technologies.

Virax Biolabs Group Limited entered into an inducement letter agreement on July 9, 2026, to facilitate the exercise of existing warrants and preferred investment options at a reduced exercise price of $6.00 per share. The company received approximately $3.3 million in gross proceeds from the holder's exercise of existing warrants. In exchange, the company will issue new Series A and Series B preferred investment options to purchase up to 1,096,000 ordinary shares. Virax Biolabs Group Limited is a biotechnology company focused on vaccine and diagnostic products.